Molecular forms of somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with senile dementia of the Alzheimer type.

Abstract

In the cerebrospinal fluid (CSF) of 53 patients with senile dementia of the Alzheimer type (SDAT) and 12 elderly controls, we measured somatostatin (SLI) and its molecular forms: high-molecular weight form (HMV-SST), somatostatin-14 (SST-14), somatostatin-25/28 (SST-28/25), and des-ala-somatostatin (des-ala-SST) using high pressure liquid chromatography (HPLC) and a radioimmunoassay. In SDAT, SLI was significantly decreased (p < 0.05) and correlated with dementia scores (r = -0.65, p < 0.05). HPLC separation showed a marked heterogeneity of SLI in the CSF with a preponderance of SST-14 and SST-25/28. The significant loss of SST-14 (p < 0.05) in SDAT was found to be correlated with dementia scores (r = 0.65). Moreover, qualitative and quantitative changes in the molecular pattern of SLI in SDAT indicated dysregulated synthesis and/or processing of somatostatin relating to the severity of dementia. The long-term administration of neuroleptics in severe cases of SDAT caused a significant increase of SLI (p < 0.05) and influenced the ratio of HMV-SST/SST-14 and SST25/28/SST-14.

• Authors: M Strittmatter, H Cramer, C Reuner, D Strubel, G Hamann, K Schimrigk
• Journal: Biological psychiatry (Biol Psychiatry) Vol. 41 Issue 11 Pg. 1124-30 (Jun 01 1997) ISSN: 0006-3223 [Print] United States
• PMID: 9146823 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Antipsychotic Agents
• Somatostatin
• Chlorpromazine

Topics

• Aged
• Alzheimer Disease (cerebrospinal fluid, drug therapy)
• Antipsychotic Agents (administration & dosage, pharmacology, therapeutic use)
• Chlorpromazine (administration & dosage, pharmacology, therapeutic use)
• Chromatography, High Pressure Liquid
• Cognition Disorders (diagnosis)
• Cross Reactions
• Female
• Humans
• Male
• Molecular Weight
• Somatostatin (biosynthesis, cerebrospinal fluid)